AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 "DURIPANC" study of Ampligen and AstraZeneca's Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders' equity of $6.9 million.
The CEO Corner segment is now available here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 [email protected]
